Menu
Close

AZN cancer drug granted breakthrough therapy designation

lse:azn

#1

AstraZeneca has announced that the US Food and Drug Administration has granted breakthrough therapy designation for Tagrisso (osimertinib) for the first-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Executive vice-president, global medicines development and chief medical officer at AstraZeneca,Sean Bohen, said: 'The breakthrough therapy designation acknowledges not only Tagrisso’s potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease. ‘The results of the FLAURA trial have the potential to redefine clinical expectations and offer new hope for patients who currently have a poor prognosis.’ Story provided by StockMarketWire.com